东诚药业(002675) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥879,736,270.21, a decrease of 1.18% compared to ¥890,215,161.87 in the same period last year[3] - Net profit attributable to shareholders was ¥54,921,850.86, down 17.90% from ¥66,898,146.52 year-on-year[3] - The net cash flow from operating activities was ¥50,759,287.12, a significant decline of 65.78% compared to ¥148,325,209.80 in the previous year[3] - Total operating revenue for the current period was ¥879,736,270.21, a decrease of 1.5% from ¥890,215,161.87 in the previous period[33] - Net profit for the current period was ¥66,193,178.35, down 25.2% from ¥88,502,966.87 in the previous period[36] - Total profit for the current period was ¥84,781,316.07, down 21.5% from ¥107,959,028.97 in the previous period[36] - Basic earnings per share decreased to ¥0.0685 from ¥0.0834, reflecting a decline of 17.7%[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,815,614,818.26, reflecting a 2.08% increase from ¥7,656,281,227.82 at the end of the previous year[3] - The total liabilities reached CNY 2,730,240,323.97, compared to CNY 2,632,511,465.23 previously, indicating an increase of about 3.7%[29] - The company's equity attributable to shareholders rose to CNY 4,437,625,628.04 from CNY 4,397,415,142.54, marking an increase of approximately 0.9%[29] - The company's current assets totaled CNY 2,917,954,395.26, slightly up from CNY 2,899,768,579.86 at the start of the year[25] - The inventory value increased to CNY 971,580,432.36 from CNY 952,527,907.65, reflecting a growth of approximately 2.2%[25] - The cash and cash equivalents decreased to CNY 726,478,148.84 from CNY 826,611,196.06, a decline of about 12.1%[22] - The accounts receivable increased to CNY 924,230,158.84 from CNY 858,219,453.02, showing a growth of approximately 7.7%[22] Revenue Sources - The company's raw material drug revenue was ¥528,794,100, an increase of 3.74% year-on-year, with gross profit rising by 57.32%[6] - The revenue from the key product, injectable nadroparin calcium, reached ¥98,500,000, marking a 21% increase year-on-year[6] - The company experienced a 38% decline in revenue from Yunk injection, totaling ¥46,430,000, primarily due to the impact of the pandemic on hospital operations[6] Cash Flow and Financing - Cash flow from operating activities generated a net amount of ¥50,759,287.12, down 65.8% from ¥148,325,209.80 in the previous period[40] - Cash inflow from investment activities totaled $194.17 million, down from $239.11 million, indicating a decrease in investment income[43] - Total cash inflow from financing activities was $124.31 million, up from $86.88 million year-over-year, reflecting increased borrowing[43] - Cash outflow for debt repayment was $138.41 million, significantly higher than $94.12 million in the previous period, indicating a focus on reducing debt[43] - The net cash flow from financing activities was -$26.35 million, worsening from -$17.29 million year-over-year, suggesting challenges in financing[43] - The ending cash and cash equivalents balance decreased to $636.29 million from $745.05 million, showing a reduction in liquidity[43] Investments and Subsidiaries - The company plans to raise up to RMB 349.997 million through a private placement of A-shares to supplement working capital and repay interest-bearing debts[15] - The company’s subsidiary, AndiTech, was recognized as a high-tech enterprise, with the certification valid for three years[18] - AndiTech signed a non-binding cooperation agreement with ImaginAb, Inc. to develop and sell licensed products in China[18] - The company received RMB 300 million in government subsidies to support the integration of the nuclear medicine industry in Yantai[18] - A subsidiary received RMB 100 million in government subsidies from the Yantai municipal government[18] - The company’s subsidiary acquired a 70.28% stake in Nanjing Yunmi Enterprise Management Partnership for RMB 35.2625 million[18] - The company plans to acquire a 99.90% stake in Nanjing Mianbei Enterprise Management Partnership for RMB 114.5184 million[18] Research and Development - Research and development expenses rose to ¥37,283,568.45, an increase of 19.5% from ¥31,104,349.40 in the previous period[33] Other Financial Metrics - Other comprehensive income after tax was -¥2,354,776.35, an improvement from -¥3,379,811.02 in the previous period[36] - Cash flow from investment activities included cash received from recovering investments of ¥187,260,000.00, down 21.4% from ¥238,000,000.00 in the previous period[40] - Cash outflow for the acquisition of fixed assets and intangible assets was $83.11 million, up from $61.97 million, reflecting increased capital expenditures[43] - The impact of exchange rate changes on cash and cash equivalents was a positive $3.12 million, compared to $2.96 million previously, indicating some currency gains[43] - The company's first-quarter report was not audited, which may affect the reliability of the financial data presented[44]